scholarly journals Focus on Therapeutic Strategies of Nonalcoholic Fatty Liver Disease

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Marilena Durazzo ◽  
Paola Belci ◽  
Alessandro Collo ◽  
Enrica Grisoglio ◽  
Simona Bo
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Adult Population ◽  
Visceral Obesity ◽  
Western World ◽  
Nonalcoholic Fatty Liver ◽  
Hepatocellular Damage ◽  
General Adult Population

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western world (it affects 30% of the general adult population). The NAFLD encompasses a histological spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), defined by steatosis, hepatocellular damage, and lobular inflammation in individuals without significant alcohol consumption and negative viral, congenital, and autoimmune liver disease markers. Currently, NAFLD is considered an emerging epidemic in light of the dramatic increase in obesity rates. With the progressive nature of NASH and its rising prevalence there is a significant need for a specific and targeted treatments since to date there has not been any validated therapies for NAFLD other than weight loss, which is well known to have a poor long-term success rate. In recent years, visceral adipose tissue has taken an important role in NAFLD pathogenesis, and current therapeutic approaches aim at reducing visceral obesity and free fatty acid overflow to the liver. This paper is focused on the treatments used for NAFLD and the potential new therapy.

scholarly journals Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers

2020 ◽  
Vol 2020 ◽  
pp. 1-16
Author(s):  
Olfa Khalifa ◽  
Khaoula Errafii ◽  
Nayla S. Al-Akl ◽  
Abdelilah Arredouani
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Molecular Mechanisms ◽  
Noncoding Rnas ◽  
Epigenetic Factors ◽  
Nonalcoholic Fatty Liver ◽  
Regulatory Pathways ◽  
Hepatocellular Damage

Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease worldwide in part due to the concomitant obesity pandemic and insulin resistance (IR). It is increasingly becoming evident that NAFLD is a disease affecting numerous extrahepatic vital organs and regulatory pathways. The molecular mechanisms underlying the nonalcoholic steatosis formation are poorly understood, and little information is available on the pathways that are responsible for the progressive hepatocellular damage that follows lipid accumulation. Recently, much research has focused on the identification of the epigenetic modifications that contribute to NAFLD pathogenesis. Noncoding RNAs (ncRNAs) are one of such epigenetic factors that could be implicated in the NAFLD development and progression. In this review, we summarize the current knowledge of the genetic and epigenetic factors potentially underlying the disease. Particular emphasis will be put on the contribution of microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs) to the pathophysiology of NAFLD as well as their potential use as therapeutic targets or as markers for the prediction and the progression of the disease.

scholarly journals From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) – New Terminology in Pediatric Patients as a Step in Good Scientific Direction?

2021 ◽  
Author(s):  
Marta Flisiak-Jackiewicz ◽  
Anna Bobrus-Chociej ◽  
Natalia Wasilewska ◽  
Dariusz Lebensztejn
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Liver Steatosis ◽  
Visceral Obesity ◽  
Metabolic Dysfunction ◽  
Nonalcoholic Fatty Liver ◽  
Set Up ◽  
End Stage

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, which predispose to more serious hepatic conditions. It ranges from simple liver steatosis to nonalcoholic steatohepatitis (NASH), which may progress to cirrhosis and even end-stage liver disease. Since obesity became one of the most important health concerns wordwide, a considerable increase in the prevalance of NAFLD and other metabolic implications has been observed, both in adults, and children. Due to the coexistence of visceral obesity, insulin resistance, dyslipidemia, NAFLD is considered to be the hepatic manifestation of metabolic syndrome (MetS). These relationship between NAFLD and MetS led to set up in adults new term combining both of these conditions, called metabolic dysfunction-associated fatty liver disease (MAFLD). Based of these findings, we propose set of criteria, which may be useful to diagnose MAFLD in children and adolescents.

scholarly journals PET/SPECT Molecular Probes for the Diagnosis and Staging of Nonalcoholic Fatty Liver Disease

2019 ◽  
Vol 18 ◽  
pp. 153601211987145 ◽  
Author(s):  
Tuo Shao ◽  
Lee Josephson ◽  
Steven H. Liang
Keyword(s):  
Computed Tomography ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Photon Emission ◽  
Molecular Probes ◽  
Western World ◽  
Emission Computed Tomography ◽  
Nonalcoholic Fatty Liver

Nonalcoholic fatty liver disease (NAFLD) is a significant public health challenge afflicting approximately 1 billion individuals both in the Western world and in the East world. While liver biopsy is considered as gold standard in the diagnosis and staging of liver fibrosis, noninvasive imaging technologies, including ultrasonography, computed tomography, single-photon emission computed tomography (SPECT), magnetic resonance imaging, and positron emission tomography (PET) could offer more sensitive, comprehensive, and quantitative measurement for NAFLD. In this review, we focus on recent development and applications of PET/SPECT molecular probes that enable multispatial/temporal visualization and quantification of physiopathological progress at the molecular level in the NAFLD. We shall also discuss the limitations of current radioligands and future direction for PET/SPECT probe development.

scholarly journals The Effect of Bariatric Surgery on the Spectrum of Fatty Liver Disease

2016 ◽  
Vol 2016 ◽  
pp. 1-3 ◽  
Author(s):  
Jordan J. Nostedt ◽  
Noah J. Switzer ◽  
Richdeep S. Gill ◽  
Jerry Dang ◽  
Daniel W. Birch ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Significant Risk ◽  
Western World ◽  
Nonalcoholic Fatty Liver ◽  
Compensated Cirrhosis ◽  
The Metabolic Syndrome

Nonalcoholic fatty liver disease is becoming one of the most common causes of liver disease in the western world. The most significant risk factors are obesity and the metabolic syndrome for which bariatric surgery has been shown to be an effective treatment. However, the effects of bariatric surgery on nonalcoholic fatty liver disease, specifically liver fibrosis and cirrhosis, are not well established. We review published bariatric surgery outcomes with respect to nonalcoholic liver disease. On the basis of this review we suggest that bariatric surgery may provide a viable treatment option for the treatment of nonalcoholic fatty liver disease, including patients with fibrosis and compensated cirrhosis, and that this topic should be a target of future investigation.

Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity

2017 ◽  
Vol 15 (10) ◽  
pp. 1604-1611.e1 ◽  
Author(s):  
Anna Ludovica Fracanzani ◽  
Salvatore Petta ◽  
Rosa Lombardi ◽  
Giuseppina Pisano ◽  
Maurizio Russello ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Visceral Obesity ◽  
Nonalcoholic Fatty Liver ◽  
Cardiovascular Damage

scholarly journals Increased Selenoprotein P Levels in Subjects with Visceral Obesity and Nonalcoholic Fatty Liver Disease

2013 ◽  
Vol 37 (1) ◽  
pp. 63 ◽  
Author(s):  
Hae Yoon Choi ◽  
Soon Young Hwang ◽  
Chang Hee Lee ◽  
Ho Cheol Hong ◽  
Sae Jeong Yang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Visceral Obesity ◽  
Selenoprotein P ◽  
Nonalcoholic Fatty Liver
Sign in / Sign up

Export Citation Format

Share Document